| calcium channel, voltage-dependent, L type, alpha 1E subunit |
FLUOXETINE |
Calcium Channel Type L, Phenylalkylamine |
94% |
1.126uM |
1.095uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
FLUOXETINE |
Calcium Channel Type L, Phenylalkylamine |
94% |
1.126uM |
1.095uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
FLUOXETINE |
Calcium Channel Type L, Phenylalkylamine |
94% |
1.126uM |
1.095uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
FLUOXETINE |
Calcium Channel Type L, Phenylalkylamine |
94% |
1.126uM |
1.095uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
FLUOXETINE |
Calcium Channel Type L, Phenylalkylamine |
94% |
1.126uM |
1.095uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
DESLORATADINE |
Calcium Channel Type L, Benzothiazepine |
73% |
5.791uM |
5.148uM |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
RESVERATROL |
CYP450-2C9 Inhibition |
73% |
7uM |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
RESVERATROL |
CYP450-2C9 Inhibition |
73% |
7uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
DOXEPIN |
Calcium Channel Type L, Benzothiazepine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
DOXEPIN |
Calcium Channel Type L, Benzothiazepine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
DOXEPIN |
Calcium Channel Type L, Benzothiazepine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
DOXEPIN |
Calcium Channel Type L, Benzothiazepine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
DOXEPIN |
Calcium Channel Type L, Benzothiazepine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
DOXEPIN |
Calcium Channel Type L, Benzothiazepine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
DOXEPIN |
Calcium Channel Type L, Benzothiazepine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
DOXEPIN |
Calcium Channel Type L, Benzothiazepine |
69% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2b |
SULPIRIDE |
Adrenergic alpha2B |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
NELFINAVIR |
Calcium Channel Type L, Phenylalkylamine |
69% |
18.38uM |
17.862uM |
View
|
| histamine receptor H 2 |
NIZATIDINE |
Histamine H2 |
69% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2b |
CYCLIZINE |
Adrenergic alpha2C |
69% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
CYCLIZINE |
Adrenergic alpha2C |
69% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
ETHYNODIOL DIACETATE |
Adrenergic, Norepinephrine Transporter |
69% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
FENOFIBRATE |
Dopamine Transporter |
69% |
8.633uM |
6.859uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
DACTINOMYCIN |
Protein Tyrosine Kinase, HER2 Receptor |
66% |
NoneNone |
NoneNone |
View
|
| v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
DACTINOMYCIN |
Protein Tyrosine Kinase, HER2 Receptor |
66% |
NoneNone |
NoneNone |
View
|
| mitogen activated protein kinase 3 |
GRAMICIDIN |
Protein Serine/Threonine Kinase, ERK1 |
66% |
NoneNone |
NoneNone |
View
|
| mitogen-activated protein kinase 3 |
GRAMICIDIN |
Protein Serine/Threonine Kinase, ERK1 |
66% |
NoneNone |
NoneNone |
View
|
| dopamine receptor D4 |
PROMAZINE |
Dopamine D4.2 |
66% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 1b |
TERCONAZOLE |
Adrenergic alpha1B |
66% |
14.299uM |
7.915uM |
View
|
| cholinergic receptor, muscarinic 2 |
PRIMAQUINE |
Muscarinic M2 |
65% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
TERCONAZOLE |
Serotonin Transporter |
66% |
11.456uM |
6.086uM |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
TERFENADINE |
Adrenergic alpha1D |
66% |
NoneNone |
NoneNone |
View
|
| mitogen activated protein kinase 3 |
NELFINAVIR |
Protein Serine/Threonine Kinase, ERK1 |
66% |
22.503uM |
NoneNone |
View
|
| mitogen-activated protein kinase 3 |
NELFINAVIR |
Protein Serine/Threonine Kinase, ERK1 |
66% |
22.503uM |
NoneNone |
View
|
| acetylcholinesterase (YT blood group) |
TERCONAZOLE |
Acetylcholinesterase |
66% |
21.573uM |
NoneNone |
View
|
| collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
TERCONAZOLE |
Acetylcholinesterase |
66% |
21.573uM |
NoneNone |
View
|
| acetylcholinesterase |
TERCONAZOLE |
Acetylcholinesterase |
66% |
21.573uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1B |
PENTAMIDINE |
Serotonin 5-HT1B |
66% |
NoneNone |
NoneNone |
View
|
| epidermal growth factor receptor |
PROCHLORPERAZINE |
Protein Tyrosine Kinase, EGF Receptor |
66% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
S-(-)-PROPRANOLOL |
Adrenergic, Norepinephrine Transporter |
66% |
NoneNone |
NoneNone |
View
|
| melanocortin 4 receptor |
GUANABENZ |
Melanocortin MC4 |
66% |
NoneNone |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 4 polypeptide |
MICONAZOLE |
ATPase, Na+/K+ |
66% |
19.279uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 3 polypeptide |
MICONAZOLE |
ATPase, Na+/K+ |
66% |
19.279uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 2 polypeptide |
MICONAZOLE |
ATPase, Na+/K+ |
66% |
19.279uM |
NoneNone |
View
|
| ATPase, Na+/K+ transporting, alpha 1 polypeptide |
MICONAZOLE |
ATPase, Na+/K+ |
66% |
19.279uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
EMETINE |
Calcium Channel Type L, Phenylalkylamine |
65% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
EMETINE |
Calcium Channel Type L, Phenylalkylamine |
65% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
EMETINE |
Calcium Channel Type L, Phenylalkylamine |
65% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
EMETINE |
Calcium Channel Type L, Phenylalkylamine |
65% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
EMETINE |
Calcium Channel Type L, Phenylalkylamine |
65% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
EMETINE |
Calcium Channel Type L, Phenylalkylamine |
65% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
EMETINE |
Calcium Channel Type L, Phenylalkylamine |
65% |
NoneNone |
NoneNone |
View
|
| opioid receptor, sigma 1 |
DIPHENHYDRAMINE |
Sigma1 |
65% |
NoneNone |
NoneNone |
View
|
| histamine receptor H 2 |
DIPHENHYDRAMINE |
Histamine H2 |
65% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
TROGLITAZONE |
Adrenergic, Norepinephrine Transporter |
65% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
RESERPINE |
Adrenergic, Norepinephrine Transporter |
65% |
NoneNone |
NoneNone |
View
|
| mu-opioid receptor MOR |
CADMIUM CHLORIDE |
Opiate mu |
65% |
NoneNone |
NoneNone |
View
|
| lymphocyte protein tyrosine kinase (mapped) |
CADMIUM CHLORIDE |
Protein Tyrosine Kinase, Lck |
65% |
NoneNone |
NoneNone |
View
|
| interleukin 8 receptor, beta |
CETYLPYRIDINIUM BROMIDE |
Chemokine CXCR2 (IL-8B) |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, beta |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 beta |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, delta |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type X, alpha |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IX, alpha |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage gated, type VIII, alpha |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VII, alpha |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, alpha |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, alpha |
SIBUTRAMINE |
Sodium Channel, Site 2 |
65% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
MAPROTILINE |
Calcium Channel Type L, Phenylalkylamine |
71% |
.446uM |
.434uM |
View
|
| lymphocyte protein tyrosine kinase (mapped) |
ERGOTAMINE |
Protein Tyrosine Kinase, Lck |
71% |
6.499uM |
NoneNone |
View
|
| adrenergic receptor, beta 2 |
ERGOTAMINE |
Adrenergic beta2 |
71% |
2.761uM |
1.898uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel associated protein 1 |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel associated protein 2 |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type III, beta |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type III, beta |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type I, beta |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type II, beta |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
PYRILAMINE |
Sodium Channel, Site 2 |
71% |
5.283uM |
4.819uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Benzothiazepine |
70% |
4.81uM |
4.275uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| histamine receptor H 2 |
NORTRIPTYLINE |
Histamine H2 |
70% |
2.334uM |
2.295uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1B |
NORTRIPTYLINE |
Serotonin 5-HT1B |
70% |
3.199uM |
1.454uM |
View
|
| adrenergic receptor, alpha 2a |
NORTRIPTYLINE |
Imidazoline I2, Central |
70% |
3.858uM |
2.572uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
NORTRIPTYLINE |
Imidazoline I2, Central |
70% |
3.858uM |
2.572uM |
View
|
| A3 adenosine receptor |
STANOZOLOL |
Adenosine A3 |
70% |
8.325uM |
4.705uM |
View
|
| adrenergic receptor, alpha 2b |
RALOXIFENE |
Adrenergic alpha2B |
70% |
3.698uM |
1.688uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
SIBUTRAMINE |
Adrenergic, Norepinephrine Transporter |
70% |
5.665uM |
5.619uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
SULCONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
69% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, beta 3 |
SULCONAZOLE |
Adrenergic beta3 |
69% |
NoneNone |
NoneNone |
View
|
| mu-opioid receptor MOR |
DANAZOL |
Opiate mu |
69% |
14.079uM |
5.715uM |
View
|
| Protein-tyrosine kinase, Fyn |
BETA-ESTRADIOL 3-BENZOATE |
Protein Tyrosine Kinase, Fyn |
69% |
22.994uM |
NoneNone |
View
|
| sodium channel associated protein 2 |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IX, alpha |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VII, alpha |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| amiloride-sensitive cation channel 5, intestinal |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, beta |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, beta |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 beta |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| monoamine oxidase A |
BETA-NAPHTHOFLAVONE |
Monoamine Oxidase MAOA |
69% |
NoneNone |
NoneNone |
View
|
| monoamine oxidase A |
BETA-NAPHTHOFLAVONE |
Monoamine Oxidase MAOA |
69% |
NoneNone |
NoneNone |
View
|
| opioid receptor, sigma 1 |
METHAPYRILENE |
Sigma1 |
69% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine receptor 6 |
DIMENHYDRINATE |
Serotonin 5-HT6 |
69% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
MYCOPHENOLATE MOFETIL |
CYP450-3A4 Inhibition |
69% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2C19 monooxygenase |
PROCHLORPERAZINE |
CYP450-2C19 Inhibition |
69% |
NoneNone |
NoneNone |
View
|
| Sigma-2 Receptor |
BUFLOMEDIL |
Sigma2 |
69% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-1A2 monooxygenase |
3,3',4',5-TETRACHLOROSALICYLANILIDE |
CYP450-1A2 Inhibition |
69% |
NoneNone |
NoneNone |
View
|